Market Cap

As of January 2, 2012: $1,912,501,000.00

Stock Chart

Mesoblast - 30 Day Poll

Recent BLOGS About Mesoblast Add New

There are no blogs to display.

Latest Company News

FDA Clearance for Phase 2 Clinical Trial in Type 2 Diabetes
irasia.com (press release) - Jan 31, 2012
Results generated from this Phase 2 trial may enable Mesoblast to expand its therapeutic programs in Type 2 diabetes and metabolic diseases to address the large unmet medical needs of Type 2 diabetes patients with renal complications and the associated ...
Mesoblast Ltd Not To Pay FY 2011 Final Dividend
Reuters Key Development - Aug 23, 2011

Website

Videos related to Mesoblast

Company Profile

Summary


Mesoblast Limited (Mesoblast) is a biotechnology company committed to the development of adult stem cell products targeting a range of bone, cartilage and musculoskeletal conditions. In late 2010 Mesoblast acquired the rest of Angioblast making the deal to buy Angioblast at $240 million.


Finance 


Jan 2012 Mesoblast reported  cash reserves of $260M.


Cardiovascular stem cell therapy: The Company holds a 38.4% interest in Angioblast Systems, Inc. (Angioblast), a company developing the same platform technology for the treatment of cardiovascular diseases, including repair and regeneration of blood vessels and heart muscle. Mesoblast is developing an allogeneic or off-the-shelf cell product, called NeoFuse, to generate bony spinal fusion.

Revascor, their proprietary "off the shelf" adult stem cell product for heart failure, have continued to show sustained improvement in heart muscle function at six months. Interim results of the ongoing phase two trial of Revascor were presented at the annual conference of the American Heart Association currently underway in Orlando, Florida. The presenter, Dr Nabil Dib associate professor of medicine and director of cell therapy, University of California, San Diego and director of cardiovascular research, Mercy Gilbert and Chandler Medical Centers, Phoenix Arizona said at six months a single dose of Revascor was accompanied by a 22% mean increase in EF whereas controls had an 18% mean decrease in EF over the same period.


Stem cells for back/disc problems: In August 2009, the United States Food and Drug Administration cleared a Phase II clinical trial of its allogeneic adult stem cells for use in minimally invasive lumbar spinal fusion surgery. The 24-patient trial, based at multiple United States sites, is comparing the effectiveness and safety of two low doses, NeoFuse with autograft in minimally invasive surgery for fusion of the lumbar spine.

Teva strategic alliance

- Teva has exclusive worldwide commercialization rights to selected cardiovascular and neurologic indications, holds 19.99% stake in Mesoblast

- Teva responsible for funding Phase 2b and Phase 3 clinical development

- Mesoblast eligible to receive up to US$1.7 billion in milestone payments, plus revenue split

- Mesoblast retains all manufacturing rights

- Mesoblast cash balance of US$260 million to fund other major indications including

     - type 2 diabetes

     - inflammatory diseases of various tissues (eg lungs) 

     - immunologic conditions (eg rheumatoid arthritis)

     - ophthalmic indications

     - orthopedic cartilage and bone conditions


Terms & Rules

As per ASIC Regulatory Guide 162: All investment tips and comments appearing on this website (Poll results, BLOGS & discussion forums) are submitted by the general public who are not licensed financial advisors. None of the information on this website is financial or investment advice, you should seek independent financial or investment advice by a licensed financial or investment advisor before entering into any position of financial risk. Before using this website, you must agree to the BioInvesting.com.au Terms Of Use

Before using this Biomedical Investing website

OR